Optimization of Natural Rhenium Irradiation Time to Produce Compositional Radiopharmaceutical

Document Type: Original Paper


1 Department of Physics, Payame Noor University, P.O.Box 19395-3697, Tehran, Iran.

2 Material and Nuclear Fuel Cycle Research School, Nuclear Science and Technology Research Institute, Tehran, Iran


Introduction: Previously, 186Re and 188Re radioisotopes have been produced through appropriate activities, and each of them has been used for therapeutic applications. The 186Re and 188Re have unique properties, which make them proper for the treatment of  tumors in different sizes. The long-range 188Re, is suitable for the annihilation of large tumors. In contrast, the short-range 186Re is desirable for the destruction of small tumors. The aim of this study was to find the suitable time for rhenium irradiation in order to simultaneously produce radionuclides with both appropriate and identical activities.
Material and Methods: To reach 186Re and 188Re with appropriate activities to produce compositional radiopharmaceutical, we have investigated natural rhenium irradiation at different times to produce 186Re and 188Re simultaneously with appropriate and identical activities to reach compositional radiopharmaceutical. In this regard, the simultaneous production of 186Re and 188Re with appropriate activities were investigated analytically through natural rhenium irradiation in a reactor. The irradiation was assessed at different time intervals in order to reach appropriate activities for compositional radiopharmaceuticals.
Results: On the basis of the findings, 186Re and 188Re could be produced simultaneously with suitable and almost equal activities with irradiating natural rhenium for 4 days and considering 1 day for cooling. Moreover, the obtained results of this study revealed that the generated impurities were negligible.
Conclusion: The optimization of natural rhenium irradiation time can help the simultaneous production of 186Re and 188Re with appropriate activities for compositional radiopharmaceuticals. 


Main Subjects

Volume 16, Issue 5
September and October 2019
Pages 362-367
  • Receive Date: 06 August 2018
  • Revise Date: 24 December 2018
  • Accept Date: 30 December 2018